Your session is about to expire
← Back to Search
Sequential ascending dose cohort for Epilepsy
Study Summary
This trial studies how 2DG pills are absorbed and distributed in patients with epilepsy to see if they can stop seizures.
- Epilepsy
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2011 Phase 2 trial • 55 Patients • NCT00062374Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have used 2DG as a treatment before.You have a brain condition that is getting worse or is expected to get worse during the study.You have experienced episodes that look like seizures but are not caused by epilepsy in the past two years.You are taking medications that affect your blood sugar levels, like steroids or certain diabetes medications.You have a serious mental or physical illness that could affect your ability to participate in the study.You have taken an experimental medication within the past 2 months.You have experienced a severe seizure that lasted a long time within the past 6 months.
- Group 1: Sequential ascending dose cohort
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are being treated in this clinical trial?
"Affirmative. Clinicaltrials.gov's records confirm that this clinical trial is actively recruiting participants, having been first posted on September 2nd 2022 and last edited on October 28th of the same year. The study requires 9 individuals from a single site to take part in it."
Is there enrollment availability for this research project?
"According to the clinicaltrials.gov database, this research project is still recruiting participants as of October 28th 2022. The study was originally posted on September 2nd 2020."
Has the Sequential ascending dose cohort received regulatory authorization?
"Our team at Power has given the safety of Sequential ascending dose cohort a score of 2, as it is currently in Phase 2 with evidence demonstrating security but no proof yet that it is effective."
Are those aged 75 or younger permissible to partake in this research endeavor?
"This research project has set the age range of 18 and 60 years old as its inclusion criteria. Simultaneously, there are 122 studies targeting participants below 18 or over 65 respectively."
Could I potentially join this clinical investigation?
"To qualify for this epilepsy trial, candidates must be between 18 and 60 years of age. In addition to confirming their diagnosis of the neurological disorder, participants should have a consistent antiepileptic treatment plan that has not changed in the last 28 days. Women capable of childbearing are also required to use contraception throughout the study and men need to abstain from fathering offspring during its duration. Finally, for enrolment consideration all individuals ought to fall within an acceptable BMI range (18-35)."
Share this study with friends
Copy Link
Messenger